Stock SPRB SPRUCE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-30 EDT 		5-day change 1st Jan Change
0.708 USD -0.28% Intraday chart for Spruce Biosciences, Inc. +0.97% -75.84%
03-15 North American Morning Briefing : Inflation -2- DJ
03-14 Top Midday Decliners MT

Evolution of the average Target Price on Spruce Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ffacfeefeae1fb81c09ee7.1TQ0lv1BrqEODNqB-Y64KbCqnFla-8GYNxr8P0p0LdU.uX0Fo88p_-VPOLu3sOLRGcfsqGAIr7KhTVK7BwxAZr6UfwDgyRH4xj1Bgw~df16ec6cdb8f3bf18e5068fd24c8dc76

Analyst Recommendations on Spruce Biosciences, Inc.

HC Wainwright Downgrades Spruce Biosciences to Neutral From Buy MT
JMP Securities Adjusts Spruce Biosciences' Price Target to $3 From $8, Maintains Market Outperform Rating MT
Leerink Partners Downgrades Spruce Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $9 MT
Guggenheim Downgrades Spruce Biosciences to Neutral From Buy MT
Ladenburg Thalmann Downgrades Spruce Biosciences to Neutral From Buy MT
Spruce Biosciences Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $2 From $9, Shares Plunge Pre-Bell; Speculative Risk Kept MT
RBC Lifts Price Target on Spruce Biosciences to $9 From $8, Cites Improved Chances of Congenital Adrenal Hyperplasia Program Success; Outperform, Speculative Risk Kept MT
Guggenheim Initiates Spruce Biosciences at Buy Rating With $10 Price Target MT
SVB Securities Upgrades Spruce Biosciences to Outperform From Market Perform, Adjusts Price Target to $9 From $3 MT
Oppenheimer Adjusts Spruce Biosciences Price Target to $7 From $8, Maintains Outperform Rating MT
JMP Securities Adjusts Spruce Biosciences' Price Target to $8 From $7, Keeps Market Outperform Rating MT
HC Wainwright Adjusts Spruce Biosciences' Price Target to $10 From $20 MT
RBC Trims Price Target on Spruce Biosciences to $8 From $9, Keeps Outperform, Speculative Risk MT
Oppenheimer Adjusts Spruce Biosciences Price Target to $8 From $13, Maintains Outperform Rating MT
JMP Securities Starts Spruce Biosciences at Market Outperform With $8 Price Target MT
SVB Leerink Adjusts Spruce Biosciences' Price Target to $3 from $5, Keeps Market Perform Rating MT
RBC Cuts Price Target on Spruce Biosciences to $9 From $13, Maintains Outperform Rating, Speculative Risk Qualifier MT
Ladenburg Thalmann Starts Spruce Biosciences at Buy With $6 Price Target MT
Credit Suisse Lowers Spruce Biosciences' Price Target to $4 from $6, Maintains Outperform Rating MT
Oppenheimer Initiates Coverage on Spruce Biosciences With Outperform Rating, $15 Price Target MT
Benchmark Initiates Coverage on Spruce Biosciences With Speculative Buy Rating MT
Cowen Downgrades Spruce Biosciences to Market Perform From Outperform MT
Credit Suisse Adjusts Spruce Biosciences' Price Target to $6 from $26, Keeps Outperform Rating MT
HC Wainwright Adjusts Price Target on Spruce Biosciences to $20 from $30, Keeps Buy Rating MT
SVB Leerink Downgrades Spruce Biosciences to Market Perform From Outperform, Adjusts Price Target to $5 From $35 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.71 USD
Average target price
2.75 USD
Spread / Average Target
+287.32%
High Price Target
4 USD
Spread / Highest target
+463.38%
Low Price Target
2 USD
Spread / Lowest Target
+181.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Spruce Biosciences, Inc.

HC Wainwright
JMP Securities
Ladenburg Thalmann
Guggenheim
Leerink Partners
RBC Capital Markets
SVB Securities LLC
Oppenheimer
SVB Leerink
Credit Suisse
Benchmark Capital
Cowen

Ratings for Spruce Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SPRB Stock
  4. Consensus Spruce Biosciences, Inc.